CryoPort (NASDAQ:CYRX) Shares Cross Above 50-Day Moving Average on Disappointing Earnings

CryoPort, Inc. (NASDAQ:CYRX) shares crossed above its fifty day moving average during trading on Friday following a better than expected earnings announcement. The stock has a fifty day moving average of $16.98 and traded as high as $19.53. CryoPort shares last traded at $19.10, with a volume of 2,585,565 shares traded.

The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.20%. The firm had revenue of $50.22 million during the quarter, compared to analysts’ expectations of $48.66 million.

Key Headlines Impacting CryoPort

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Third-quarter revenue rose 14% year over year to $50.2 million, topping estimates of $48.66 million. Commercial cell and gene therapy revenue grew 20%; Cryoport supported a record 788 global clinical trials and 23 commercially approved therapies. Cryoport Reports Third Quarter 2026 Financial Results
• Positive Sentiment: The company raised its full-year 2026 revenue outlook to $197 million–$199 million, a key catalyst behind the favorable reaction to results. CryoPort Shares Rise After Q3 Revenue Beat, 2026 Guidance Raise
• Positive Sentiment: Analyst actions added support: Needham raised its price target to $28 from $19 and reiterated Buy, while KeyCorp lifted its target to $20 from $17 and maintained an Overweight rating. Needham Adjusts Price Target KeyCorp Rating
• Negative Sentiment: Adjusted earnings were a loss of $0.25 per share, missing consensus estimates of a $0.18–$0.19 loss and widening from a $0.18 loss a year earlier. The earnings shortfall may temper optimism around the revenue growth and raised outlook. CryoPort Reports Q3 Loss, Tops Revenue Estimates

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Robert W. Baird set a $26.00 target price on shares of CryoPort in a report on Tuesday, October 13th. Needham & Company LLC upped their target price on CryoPort from $19.00 to $28.00 and gave the company a “buy” rating in a report on Friday. Piper Sandler upgraded CryoPort to a “buy” rating in a research report on Tuesday, October 13th. Roth Capital reaffirmed a “buy” rating and set a $21.00 target price on shares of CryoPort in a report on Friday, August 7th. Finally, KeyCorp lifted their price target on shares of CryoPort from $17.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, CryoPort presently has an average rating of “Moderate Buy” and a consensus price target of $21.69.

Insider Buying and Selling

In related news, CEO Jerrell Shelton sold 28,800 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $14.91, for a total transaction of $429,408.00. Following the completion of the transaction, the chief executive officer directly owned 1,201,814 shares of the company’s stock, valued at approximately $17,919,046.74. This represents a 2.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 9.50% of the company’s stock.

Institutional Investors Weigh In On CryoPort

Hedge funds have recently added to or reduced their stakes in the business. State of Alaska Department of Revenue acquired a new stake in shares of CryoPort during the 3rd quarter worth about $40,000. State of Wyoming bought a new stake in CryoPort in the third quarter valued at $81,000. Counterpoint Mutual Funds LLC acquired a new stake in shares of CryoPort during the third quarter worth $324,000. Highland Investment Advisors LLC acquired a new position in CryoPort during the second quarter valued at approximately $306,000. Finally, Kerrisdale Advisers LLC bought a new stake in CryoPort in the 2nd quarter valued at about $355,000. 92.90% of the stock is currently owned by institutional investors and hedge funds.

CryoPort Stock Performance

The stock has a market capitalization of $967.42 million, a P/E ratio of -19.69 and a beta of 1.89. The stock’s fifty day simple moving average is $16.98 and its two-hundred day simple moving average is $13.46.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) provides temperature-controlled supply chain solutions for the life sciences industry. The company supports the transportation, storage and management of biological materials, including cell and gene therapies, vaccines, biologics, reproductive materials and other temperature-sensitive products.

Its offerings include cryogenic and refrigerated shipping containers, biological material storage, transportation logistics, shipment monitoring and related supply chain management services.